$PCSA insider trading
Over the last 12 months, Processa Pharmaceuticals insiders reported 36 buys totaling $178K and no sales across SEC Form 4 filings.
- Bought · 12m
- $178K 36 events
- Sold · 12m
- — 0 events
- Events · 12m
- 36 Form 4 filings, grouped
- Insiders · 12m
- 9 distinct reporters
- 10b5-1 share
- 0% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Ng George KChief Executive Officer · O·D | ▲ Buy | 3,057 | $1.93 | $6K | +24.6% | — |
| Jun 30, 2026 | Guy WendyChief Administrative Officer · O | ▲ Buy | 2,436 | $1.93 | $5K | +20.4% | — |
| Jun 30, 2026 | Lin PatrickChief Business - Strategy Off · O | ▲ Buy | 2,106 | $1.93 | $4K | +19.1% | — |
| Jun 30, 2026 | SKIBSTED RUSSELLChief Financial Officer · O | ▲ Buy | 3,277 | $1.93 | $6K | +24.4% | — |
| Jun 30, 2026 | Young DavidPres. Research & Development · O·D | ▲ Buy | 2,531 | $1.93 | $5K | +13.2% | — |
| Jun 15, 2026 | Young DavidPres. Research & Development · O·D | ▲ Buy | 2,067 | $2.22 | $5K | +12.1% | — |
| Jun 15, 2026 | SKIBSTED RUSSELLChief Financial Officer · O | ▲ Buy | 2,654 | $2.22 | $6K | +24.7% | — |
| Jun 15, 2026 | Ng George KChief Executive Officer · O·D | ▲ Buy | 2,465 | $2.22 | $5K | +24.7% | — |
| Jun 15, 2026 | Lin PatrickChief Business - Strategy Off · O | ▲ Buy | 1,831 | $2.22 | $4K | +20% | — |
| Jun 15, 2026 | Guy WendyChief Administrative Officer · O | ▲ Buy | 2,118 | $2.22 | $5K | +21.5% | — |
| May 29, 2026 | Young DavidPres. Research & Development · O·D | ▲ Buy | 1,786 | $2.57 | $5K | +11.6% | — |
| May 29, 2026 | SKIBSTED RUSSELLChief Financial Officer · O | ▲ Buy | 2,292 | $2.57 | $6K | +27.1% | — |
| May 29, 2026 | Ng George KChief Executive Officer · O·D | ▲ Buy | 2,129 | $2.57 | $5K | +27.2% | — |
| May 29, 2026 | Lin PatrickChief Business - Strategy Off · O | ▲ Buy | 1,582 | $2.57 | $4K | +20.8% | — |
| May 29, 2026 | Guy WendyChief Administrative Officer · O | ▲ Buy | 1,829 | $2.57 | $5K | +22.8% | — |
| Apr 30, 2026 | Young DavidPres. Research & Development · O·D | ▲ Buy | 1,706 | $2.69 | $5K | +14.1% | — |
| Apr 30, 2026 | SKIBSTED RUSSELLChief Financial Officer · O | ▲ Buy | 2,190 | $2.69 | $6K | +50.8% | — |
| Apr 30, 2026 | Ng George KChief Executive Officer · O·D | ▲ Buy | 2,034 | $2.69 | $5K | +51.1% | — |
| Apr 30, 2026 | Lin PatrickChief Business - Strategy Off · O | ▲ Buy | 1,511 | $2.69 | $4K | +32% | — |
| Apr 30, 2026 | Guy WendyChief Administrative Officer · O | ▲ Buy | 1,748 | $2.69 | $5K | +37.2% | — |
| Apr 30, 2026 | Bigora SianChief Development Officer · O | ▲ Buy | 1,986 | $2.69 | $5K | +36% | — |
| Apr 15, 2026 | Young DavidPres. Research & Development · O·D | ▲ Buy | 1,545 | $2.97 | $5K | +14.6% | — |
| Apr 15, 2026 | Ng George KChief Executive Officer · O·D | ▲ Buy | 1,843 | $2.97 | $5K | +50.5% | — |
| Apr 15, 2026 | Lin PatrickChief Business - Strategy Off · O | ▲ Buy | 1,369 | $2.97 | $4K | +40.8% | — |
| Apr 15, 2026 | Guy WendyChief Administrative Officer · O | ▲ Buy | 1,583 | $2.97 | $5K | +50.9% | — |
| Apr 15, 2026 | Bigora SianChief Development Officer · O | ▲ Buy | 1,799 | $2.97 | $5K | +48.5% | — |
| Apr 15, 2026 | SKIBSTED RUSSELLChief Financial Officer · O | ▲ Buy | 1,984 | $2.97 | $6K | +85.4% | — |
| Mar 31, 2026 | Neal James RD | ▲ Buy | 789 | $2.54 | $2K | +2720.7% | — |
| Mar 31, 2026 | Young DavidPres. Research & Development · O·D | ▲ Buy | 1,810 | $2.54 | $5K | +20.7% | — |
| Mar 31, 2026 | SKIBSTED RUSSELLChief Financial Officer · O | ▲ Buy | 2,324 | $2.54 | $6K | — | — |
| Mar 31, 2026 | Pannu GeraldineD | ▲ Buy | 2,072 | $2.54 | $5K | +1786.2% | — |
| Mar 31, 2026 | Ng George KChief Executive Officer · O·D | ▲ Buy | 2,136 | $2.54 | $5K | +141.2% | — |
| Mar 31, 2026 | Lin PatrickChief Business - Strategy Off · O | ▲ Buy | 1,603 | $2.53 | $4K | +91.4% | — |
| Mar 31, 2026 | Guy WendyChief Administrative Officer · O | ▲ Buy | 1,854 | $2.54 | $5K | +147.6% | — |
| Mar 31, 2026 | Bigora SianChief Development Officer · O | ▲ Buy | 2,107 | $2.53 | $5K | +131.4% | — |
| Mar 31, 2026 | Baluch KhosoD | ▲ Buy | 2,269 | $2.54 | $6K | +4051.8% | — |
Every $PCSA filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Processa Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $PCSA feed.